Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · March 28, 2024

Impact of Initial Tumor Response on Survival Outcomes in Patients With HER2+ Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab

Clinical Breast Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Breast Cancer
The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial
Clin. Breast Cancer 2024 Feb 21;[EPub Ahead of Print], V Debien, E Agostinetto, M Bruzzone, M Ceppi, D Martins-Branco, C Molinelli, F Jacobs, G Nader-Marta, M Lambertini, E de Azambuja

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading